SynthesisJournal of clinical hypertension (Greenwich, Conn.)2015
Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis.
Synthesis in Journal of clinical hypertension (Greenwich, Conn.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05253781 (Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy), which is not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial
Who cites it
32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 97 citations in OpenAlex.
- Pravastatin in preeclampsia: A meta-analysis and systematic review.Frontiers in medicine · 2022Pooled it
- Antiplatelet agents for preventing pre-eclampsia and its complications.The Cochrane database of systematic reviews · 2019Pooled it
- Low-Dose Aspirin for Preventing Preeclampsia and Its Complications: A Meta-Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2015Pooled it
- Guideline adherence to aspirin prophylaxis use for preeclampsia among healthcare providers in Northwest Ethiopia: an explanatory sequential mixed-methods study.AJOG global reports · 2026Article
- Inflammation at the Maternal-Fetal Interface: Mechanisms Linking Maternal-Fetal Immunity to Preeclampsia and Fetal Growth Restriction.International journal of molecular sciences · 2026Review
- Coagulation dysfunction as an independent predictor of early pregnancy loss in women with polycystic ovary syndrome: a machine learning-based retrospective cohort study.Frontiers in endocrinology · 2026Article
- The Nationwide Impact of Guidelines for Prophylactic Aspirin Treatment for Preeclampsia.Paediatric and perinatal epidemiology · 2026Article
- Review
- SIRT5 suppresses the trophoblast cell proliferation, invasion, and migration to promote preeclampsia via desuccinylating HOXB3.Journal of assisted reproduction and genetics · 2024Article
- Recent Advances in the Prevention and Screening of Preeclampsia.Journal of clinical medicine · 2023Review
- Evaluation of impacts of aspirin therapy versus placebo on preeclampsia: An observational study.Heliyon · 2023Article
- Low-Dose Aspirin after ASPRE-More Questions Than Answers? Current International Approach after PE Screening in the First Trimester.Biomedicines · 2023Review
- Risk of adverse neonatal outcomes among pregnant women with disabilities.International journal of epidemiology · 2023Article
- Efficacy and safety of low-dose aspirin combined with low-molecular-weight heparin in treatment of preeclampsia: a meta-analysis and systematic review.Archives of medical science : AMS · 2022Review
- Reducing the Risk of Preterm Preeclampsia: Comparison of Two First Trimester Screening and Treatment Strategies in a Single Centre in Switzerland.Geburtshilfe und Frauenheilkunde · 2021Article
- Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.The Journal of clinical endocrinology and metabolism · 2021Article
- Association between pre-pregnancy calcium intake and hypertensive disorders during the first pregnancy: the Japan environment and children's study.BMC pregnancy and childbirth · 2020Article
- Diagnostic Performance of First Trimester Screening of Preeclampsia Based on Uterine Artery Pulsatility Index and Maternal Risk Factors in Routine Clinical Use.Diagnostics (Basel, Switzerland) · 2020Article
- Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy.International journal of molecular sciences · 2019Review
- Incidence and risk factors for Preeclampsia in a cohort of healthy nulliparous pregnant women: a nested case-control study.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low-dose aspirin (LDA) is thought to prevent preeclampsia in high-risk pregnancy, but it is not universally used out of concern for its efficacy and safety. The authors meta-analyzed 29 randomized controlled trials (RCTs) to evaluate LDA for preventing preeclampsia and its complications. LDA can reduce the incidence of preeclampsia (odds ratio [OR], 0.71; 95% confidence interval [CI], 0.57-0.87), severe preeclampsia (OR, 0.37; 95% CI, 0.23-0.61), preterm birth (OR, 0.81; 95% CI, 0.75-0.88), and intrauterine growth restriction (IUGR) (OR, 0.80; 95% CI, 0.71-0.90). LDA is more effective in reducing incidence of preeclampsia or IUGR if used before 16 gestational weeks than if used later. LDA increases the incidence of placental abruption (OR, 1.35; 95% CI, 1.05-1.73) but not other major complications. The available evidence suggests that LDA is effective in preventing preeclampsia, preterm birth, and IUGR in high-risk pregnancies without posing a major safety risk to mothers or fetuses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.